Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
WEB5 days ago · Pleural mesothelioma is a type of cancer which develops in the tissue that lines the lungs or pleura. This is the first time Keytruda has been approved for the given indication in the United States.
FDA Approves Pembrolizumab/Chemo in Unresectable Pleural Mesothelioma
WEBSep 17, 2024 · A treatment regimen consisting of pembrolizumab (Keytruda) plus pemetrexed and platinum-based chemotherapy has earned FDA approval as a first-line therapy for patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM), according to a press release from the agency. 1. The regulatory agency approved pembrolizumab at a ...
New FDA approval for mesothelioma treatment | Belluck & Fox LLP
WEB5 days ago · Mesothelioma treatment has lagged behind other cancers. Its first FDA-approval came in 2004 when Alimta plus cisplatin chemotherapy extended median survival by 3 months (from 9 months to 12 months). For over 16 years, mesothelioma didn’t see any new treatments added to its line-up until 2020 when a landmark study of two immunotherapy agents ...
New Drug to Treat Mesothelioma Hailed as a Major Breakthrough
WEBFeb 21, 2024 · ADI-PEG20 or pegargiminase is being hailed as the first drug of its kind to be incorporated successfully with chemotherapy in 20 years. Researchers say this new drug could bring hope to thousands of mesothelioma survivors and their families. The drug blocks the cancer’s food supply, ensuring the disease can’t spread.
Cancer Breakthrough: Innovative Mesothelioma Treatment …
WEBFeb 29, 2024 · The phase 3 clinical trial, led by Professor Peter Szlosarek at Queen Mary and sponsored by Polaris Pharmaceuticals, has unveiled a breakthrough in the treatment of malignant pleural mesothelioma (MPM), a rare and often rapidly fatal form of cancer with limited therapeutic options.
Phase 3 Keytruda, Chemo Mesothelioma Trial Shows Promise
WEBJun 26, 2023 · Pharmaceutical company Merck says use of its immunotherapy drug Keytruda in conjunction with chemotherapy increases the survival rate for people with advanced pleural mesothelioma, according to the latest results of a phase 3 clinical trial.
FDA Approves Drug Combination for Treating Mesothelioma
WEBOct 2, 2020 · Today, the FDA approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery.
FDA Grants Fast Track Designation to UV1 Vaccine Combo in …
WEBFeb 6, 2024 · The FDA has granted fast track designation to UV1, an investigational cancer vaccine, plus nivolumab (Opdivo) and ipilimumab (Yervoy) in the management of unresectable malignant pleural mesothelioma, according to a press release from Ultimovacs ASA, the developer of the vaccine. 1
Understanding the new therapeutic options for mesothelioma
WEBSep 6, 2021 · However, in October, 2020, the FDA-approved first-line treatment for mesothelioma was changed to ipilimumab plus nivolumab due to the compelling data from CheckMate 743. Although RAMES offers another option, it is unclear where it fits into this new treatment paradigm.
Immunotherapy approaches for malignant pleural mesothelioma
WEBJul 1, 2022 · In mesothelioma, a rare cancer with a dismal prognosis generally caused by exposure to asbestos, treatment with single or dual ICIs results in robust improvements in overall survival over...
Skip to content